Overview

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

This Phase 3 study was designed to confirm the efficacy and safety of eliglustat tartrate (Genz-112638) in participants with Gaucher disease type 1 who had reached therapeutic goals with enzyme replacement therapy (ERT).

Phase:

Phase 3

Details

Lead Sponsor:

Genzyme, a Sanofi Company

Treatments:

Eliglustat